The most significant advance in the medical management of HIV-1 infection has been the
treatment of patients with antiviral drugs, which can suppress HIV-1 replication to …

Currently, it is estimated that 1–2 million people worldwide are infected with HIV-2,
accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer …

Antiretroviral therapy has led to a significant decrease in human immunodeficiency virus
(HIV)-related mortality. Approved antiretroviral drugs target different steps of the viral life …

Currently, 20 drugs have been approved for Human Immunodeficiency Virus type-1 (HIV-1)
clinical therapy. These drugs inhibit HIV-1 reverse transcriptase, protease, or virus entry …

The introduction of potent combination therapies in the mid-90s had a tremendous effect on
AIDS mortality. However, drug resistance has been a major factor contributing to …

Inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and
protease (PR) are widely used in the clinical treatment of AIDS. However, the emergence of …

The availability of combined antiretroviral therapy (cART) has revolutionized the course of
HIV infection, suppressing HIV viremia, restoring the immune system, and improving the …

Highly active antiretroviral therapy (HAART) consists of a combination of drugs to achieve
maximal virological response and reduce the potential for the emergence of antiviral …

One to two million people worldwide are infected with the human immunodeficiency virus
type 2 (HIV-2), with highest prevalences in West African countries, but also present in …

Antiretroviral drug resistance is a fundamental survival strategy for the virus that stems from
its vast capacity to generate diversity. With the recent availability of new ARV drugs and …